Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Yahong Meditech Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity involves 1 distinct examiner. Such a narrow distribution reflects a singular point of contact within the USPTO for the company's current pending matters. This concentration allows for a highly focused prosecution strategy.
The busiest examiner, STEINKE, SEAN JAMES, is assigned the busiest examiner pending office action. This represents the total volume of pending actions for the portfolio, meaning the company's immediate prosecution outcomes are tied to the review of this specific examiner. The presence of a single distinct art unit further localizes the regulatory environment for these filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632521 | PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE, NITROXOLINE ORAL SOLID TABLET, PREPARATION METHOD THEREFOR AND USE THEREOF | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632521 | PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE, NITROXOLINE ORAL SOLID TABLET, PREPARATION METHOD THEREFOR AND USE THEREOF | STEINKE, SEAN JAMES | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17632521 | PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE, NITROXOLINE ORAL SOLID TABLET, PREPARATION METHOD THEREFOR AND USE THEREOF | STEINKE, SEAN JAMES | 1619 | §102§103Other | Non-Final OA | — | Pending | Feb 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Yahong Meditech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean James Steinke has the most, with 1 of Shanghai Yahong Meditech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
